| Year |
Citation |
Score |
| 2020 |
Denu RA, Burkard ME. Analysis of the "centrosome-ome" identifies MCPH1 deletion as a cause of centrosome amplification in human cancer. Scientific Reports. 10: 11921. PMID 32681070 DOI: 10.1038/S41598-020-68629-4 |
0.323 |
|
| 2020 |
Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, Choudhary A, Garcia-Valera R, Burkard ME, McGregor SM, Matkowskyj KA, Parikh AA, Meszoely IM, Kelley MC, Tsai S, et al. Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment. Frontiers in Oncology. 10: 553. PMID 32500020 DOI: 10.3389/Fonc.2020.00553 |
0.356 |
|
| 2020 |
Singh A, Denu RA, Wolfe SK, Sperger JM, Schehr J, Witkowsky T, Esbona K, Chappell RJ, Weaver BA, Burkard ME, Lang JM. Centrosome amplification is a frequent event in circulating tumor cells from subjects with metastatic breast cancer. Molecular Oncology. PMID 32255253 DOI: 10.1002/1878-0261.12687 |
0.335 |
|
| 2020 |
Parsons BM, Meier DR, Richmond CS, Gurda GT, Lofgren KA, Burkard ME, Deming DA, Kenny PA. Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer. Clinical Breast Cancer. PMID 32234363 DOI: 10.1016/J.Clbc.2020.02.003 |
0.365 |
|
| 2020 |
Emmerich P, Matkowskyj KA, McGregor S, Kraus S, Bischel K, Qyli T, Buehler D, Pasch C, Babiarz C, Depke M, Clipson L, Wisinski KB, Burkard ME, Baschnagel A, Uboha NV, et al. VCAN accumulation and proteolysis as predictors of T lymphocyte-excluded and permissive tumor microenvironments. Journal of Clinical Oncology. 38: 3127-3127. DOI: 10.1200/Jco.2020.38.15_Suppl.3127 |
0.344 |
|
| 2020 |
Rocque G, Gilbert A, Williams CP, Nakhmani A, Kandhare PG, Azuero A, Bhatia S, Kenzik KM, Burkard ME. Abstract P2-15-05: Visualization of the relationship between survival and sequential treatments in metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P2-15-05 |
0.341 |
|
| 2020 |
Wildiers H, Boni V, Saura C, Oliveira M, Jhaveri K, Won H, Bidard F, Brufsky AM, Burkard ME, Cervantes A, Fernández-Martos C, Haley B, Loi S, Spanggaard I, Panni S, et al. Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P1-19-08 |
0.384 |
|
| 2020 |
Hu Y, Jin N, Manasrah BK, McGregor SM, Scribano C, Tucker JB, Yan R, Lera RF, Weaver BA, Burkard ME. Abstract 2248: Paclitaxel-induced micronucleation activates pro-inflammatory cGAS/STING signaling in triple negative breast cancer Immunology. DOI: 10.1158/1538-7445.Am2020-2248 |
0.332 |
|
| 2019 |
Pasch CA, Favreau PF, Yueh AE, Babiarz CP, Gillette A, Sharick JT, Karim MR, Nickel KP, DeZeeuw AK, Sprackling CM, Emmerich PB, DeStefanis RA, Pitera RT, Payne SN, Korkos DP, ... ... Burkard ME, et al. Patient-derived cancer organoid cultures to predict sensitivity to chemotherapy and radiation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31175091 DOI: 10.1158/1078-0432.Ccr-18-3590 |
0.338 |
|
| 2019 |
Gilbert A, Kandhare P, Nakhmani A, Meersman SC, Garrett-Mayer E, Kaltenbaugh M, Burkard ME, Williams C, Azuero A, Bhatia S, Kenzik K, Rocque GB. Utilizing visualization to qualitatively evaluate electronic health record-derived database limitations. Journal of Clinical Oncology. 37: 317-317. DOI: 10.1200/Jco.2019.37.27_Suppl.317 |
0.343 |
|
| 2019 |
Gilbert A, Williams C, Kandhare P, Nakhmani A, Meersman SC, Garrett-Mayer E, Kaltenbaugh M, Azuero A, Ingram SA, Burkard ME, Bhatia S, Kenzik K, Rocque GB. Visualizing treatment patterns and survival in metastatic breast cancer. Journal of Clinical Oncology. 37: 316-316. DOI: 10.1200/Jco.2019.37.27_Suppl.316 |
0.321 |
|
| 2019 |
Matrana MR, Tomlins SA, Kwiatkowski K, Mitchell K, Suga JM, Dees EC, Burkard ME, Khatri J, Safa MM, Yang ES, Parsons B, Menter AR, Thompson MA, Gonzalez AO, Wassenaar TR, et al. No-cost next generation sequencing of advanced cancer patients within the Strata Precision Oncology Network supports clinical trial enrollment. Journal of Clinical Oncology. 37: 3073-3073. DOI: 10.1200/Jco.2019.37.15_Suppl.3073 |
0.311 |
|
| 2019 |
Yan R, Longhurst C, Lee K, Gilbert A, Alexandridis R, McGregor S, Laffin J, Rocque G, Burkard M. Abstract P3-06-14: Whole exome analysis of extreme long-term survivors with metastatic breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P3-06-14 |
0.341 |
|
| 2019 |
Burkard M, Lemmon K, Gilbert A, Zhang X, Trentham-Dietz A, Dahl E, Rocque G. Abstract P1-08-15: Characteristics of long-term survivors with metastatic breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P1-08-15 |
0.365 |
|
| 2019 |
Sharifi M, Wisinski K, Burkard M, Tevaarwerk A, Tamkus D, Chan N, Truica C, Danciu O, Hoskins K, O'Regan R. Abstract OT1-02-01: Phase I trial of bicalutamide and ribociclib in androgen receptor-positive triple negative breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot1-02-01 |
0.365 |
|
| 2019 |
Sprackling CM, Kratz JD, Favreau PF, Karim MR, Babiarz CP, Pasch CA, Gillette AA, Clipson L, Matkowskyj KA, Eichoff JC, Lemmon KK, Houtler HK, Burkard ME, Miller D, Skala MC, et al. Abstract 3143: Predicting treatment response using patient derived organotypic cancer spheroids Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3143 |
0.331 |
|
| 2019 |
Kratz J, Uboha N, Lemmon K, Houtler H, Burkard M, Deming D. Abstract 1414: Durable response to first-line Trastuzumab in HER2 amplified colorectal cancer Cancer Research. 79: 1414-1414. DOI: 10.1158/1538-7445.Am2019-1414 |
0.367 |
|
| 2018 |
Fricke SL, Payne SN, Favreau PF, Kratz JD, Pasch CA, Foley TM, Yueh AE, Van De Hey DR, Depke MG, Korkos DP, Sha GC, DeStefanis RA, Clipson L, Burkard ME, Lemmon KK, et al. MTORC1/2 inhibition as a therapeutic strategy for PIK3CA mutant cancers. Molecular Cancer Therapeutics. PMID 30425131 DOI: 10.1158/1535-7163.Mct-18-0510 |
0.343 |
|
| 2018 |
Jin N, Burkard ME. MACROD2, an Original Cause of CIN? Cancer Discovery. 8: 921-923. PMID 30076143 DOI: 10.1158/2159-8290.Cd-18-0674 |
0.303 |
|
| 2018 |
Denu RA, Shabbir M, Nihal M, Singh CK, Longley BJ, Burkard ME, Ahmad N. Centriole Overduplication is the Predominant Mechanism Leading to Centrosome Amplification in Melanoma. Molecular Cancer Research : McR. PMID 29330283 DOI: 10.1158/1541-7786.Mcr-17-0197 |
0.308 |
|
| 2018 |
Sharick J, Walsh A, Sanders M, Kelley M, Meszoely I, Hooks M, Burkard M, Esbona K, Choudhary A, Skala M. Abstract P5-01-01: Personalized neoadjuvant treatment planning using optical metabolic imaging Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P5-01-01 |
0.373 |
|
| 2018 |
Esbona K, Jin N, Correia-Staudt K, Lager A, Heidke T, Laffin J, Weaver B, Burkard M. Abstract P4-03-09: Chromosomal instability predicts taxane sensitivity in breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-09 |
0.395 |
|
| 2018 |
Ejebe I, Denu R, Longhurst C, Bauman J, MacGregor S, Lee K, Burkard M. Abstract P3-04-05: Outliers—extreme long-term survivors with metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P3-04-05 |
0.386 |
|
| 2018 |
Jin N, Burkard M. Abstract 3797: Chromosome instability as a prognostic factor& an immunotherapeutic target in acute myeloid leukemia Cancer Research. 78: 3797-3797. DOI: 10.1158/1538-7445.Am2018-3797 |
0.321 |
|
| 2018 |
Singh A, Denu RA, Sperger JM, Weaver BA, Burkard ME, Lang JM. Abstract 3604: Centrosome amplification in epcam-captured circulating tumor cells from metastatic cancer patients Cancer Research. 78: 3604-3604. DOI: 10.1158/1538-7445.Am2018-3604 |
0.375 |
|
| 2017 |
Ma CX, Suman V, Goetz MP, Northfelt DW, Burkard ME, Ademuyiwa F, Naughton MJ, Margenthaler J, Aft R, Gray RJ, Tevaarwerk AJ, Wilke LG, Haddad TC, Moynihan T, Loprenzi C, et al. A Phase II trial of neoadjuvant MK2206, an AKT inhibitor, with anastrozole in clinical stage 2 or 3 PIK3CA mutant ER positive and HER2 negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28874413 DOI: 10.1158/1078-0432.Ccr-17-1260 |
0.355 |
|
| 2017 |
Denu RA, Burkard ME. Synchronous Bilateral Breast Cancer in a Patient With Nager Syndrome. Clinical Breast Cancer. PMID 28139434 DOI: 10.1016/J.Clbc.2016.12.009 |
0.347 |
|
| 2017 |
Denu RA, Burkard ME. Abstract A01: Centrosome amplification induces autophagy and sensitizes to chloroquine Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A01 |
0.314 |
|
| 2017 |
Tevaarwerk A, Buhr K, Conkright W, Onitilo A, Robinson E, Hegeman R, Ahuja H, Kwong R, Nanad R, Dennee A, Koehn T, Burkard M, Wisinski K, Wiegmann D, Sesto M. Abstract P5-13-03: Prospective study of work limitations in breast cancer patients (pts) undergoing curative chemotherapy (CTx) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P5-13-03 |
0.362 |
|
| 2017 |
Singh A, Sperger JM, Schehr J, Witkowski T, Weaver BA, Burkard ME, Lang JM. Abstract 3784: Expression of estrogen receptor specific signaling transcriptome in epithelial cell adhesion molecule (EpCAM) captured circulating tumor cells from patients with breast cancer Cancer Research. 77: 3784-3784. DOI: 10.1158/1538-7445.Am2017-3784 |
0.343 |
|
| 2016 |
Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational New Drugs. PMID 27826831 DOI: 10.1007/S10637-016-0403-2 |
0.334 |
|
| 2016 |
Wisinski KB, Xu W, Tevaarwerk AJ, Saha S, Kim K, Traynor A, Dietrich L, Hegeman R, Patel D, Blank J, Harter J, Burkard ME. Targeting Estrogen Receptor Beta in a Phase 2 Study of High-Dose Estradiol in Metastatic Triple-Negative Breast Cancer: A Wisconsin Oncology Network Study. Clinical Breast Cancer. PMID 27133732 DOI: 10.1016/J.Clbc.2016.03.005 |
0.333 |
|
| 2016 |
Wisinski KB, Tevaarwerk AJ, Burkard ME, Rampurwalla M, Eickhoff J, Bell MC, Kolesar JM, Flynn C, Liu G. Phase 1 study of an AKT-inhibitor (MK-2206) combined with lapatinib in adult solid tumors followed by dose-expansion in advanced HER2+ breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27026198 DOI: 10.1158/1078-0432.Ccr-15-2365 |
0.34 |
|
| 2016 |
Denu RA, Zasadil LM, Kanugh C, Laffin J, Weaver BA, Burkard ME. Centrosome amplification induces high grade features and is prognostic of worse outcomes in breast cancer. Bmc Cancer. 16: 47. PMID 26832928 DOI: 10.1186/S12885-016-2083-X |
0.353 |
|
| 2016 |
Rampurwala M, Choudhary A, Burkard M. Abstract P6-13-16: Ropidoxuridine (IPdR) potentiates alisertib (MLN8237) activity in triple-negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-13-16 |
0.412 |
|
| 2016 |
Ma C, Suman V, Goetz M, Northfelt D, Burkard M, Ademuyiwa F, Naughton M, Margenthaler J, Aft R, Gray R, Tavaarwerk A, Wilke L, Haddad T, Moynihan T, Loprinzi C, et al. Abstract P5-13-04: A phase II neoadjuvant trial of MK-2206, an AKT inhibitor, in combination with anastrozole for clinical stage 2 or 3 PIK3CA mutant estrogen receptor positive HER2 negative (ER+HER2-) breast cancer (BC) Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-13-04 |
0.338 |
|
| 2016 |
Cavalcante L, Denu R, Zasadil L, Weaver B, Burkard M. Abstract P3-07-53: Chromosomal instability as a predictor of sensitivity to paclitaxel Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-53 |
0.41 |
|
| 2015 |
Choudhary A, Zachek B, Lera RF, Zasadil LM, Lasek A, Denu RA, Kim H, Kanugh C, Laffin J, Harter JM, Wisinski KB, Saha S, Weaver BA, Burkard ME. Identification of selective lead compounds for treatment of high-ploidy breast cancer. Molecular Cancer Therapeutics. PMID 26586723 DOI: 10.1158/1535-7163.Mct-15-0527 |
0.398 |
|
| 2015 |
Denu RA, Burkard ME. Centrosome amplification and prognosis in breast cancer. Journal of Clinical Oncology. 33: 11036-11036. DOI: 10.1200/Jco.2015.33.15_Suppl.11036 |
0.34 |
|
| 2015 |
Nazeef M, Tevaarwerk AJ, Eickhoff J, Burkard ME, Heideman J, Liu G, Flynn C, Kolesar JM, Wisinski KB. Abstract P5-19-20: A phase I study of MK-2206 in combination with lapatinib in patients with advanced solid tumors followed by dose-expansion in advanced HER2+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P5-19-20 |
0.373 |
|
| 2015 |
Tevaarwerk AJ, Buhr KA, Wisinski KB, Burkard M, Gribble M, Hocking W, Sun W, Donohue S, Zeal J, Terhaar A, Wiegman DA, Sesto ME. Abstract P1-09-15: Randomized clinical trial assessing the impact of survivorship care plans on survivor knowledge Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-09-15 |
0.327 |
|
| 2014 |
Robins HI, Burkard ME, Halberg RB. "TRIMing" the patient population to increase the benefit of mTOR inhibition. Journal of the National Cancer Institute. 106. PMID 24777109 DOI: 10.1093/Jnci/Dju095 |
0.343 |
|
| 2014 |
Zasadil LM, Andersen KA, Yeum D, Rocque GB, Wilke LG, Tevaarwerk AJ, Raines RT, Burkard ME, Weaver BA. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Science Translational Medicine. 6: 229ra43. PMID 24670687 DOI: 10.1126/Scitranslmed.3007965 |
0.368 |
|
| 2014 |
Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clinical Breast Cancer. 14: 205-11. PMID 24342730 DOI: 10.1016/J.Clbc.2013.10.018 |
0.351 |
|
| 2014 |
Rampurwala MM, Burkard ME, Wisinski KB, Chimeh SE, Zeal J, Koehn T, Champeny TL, Rettig J, Kim K, Kolesar J, Tevaarwerk A. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Journal of Clinical Oncology. 32: 538-538. DOI: 10.1200/Jco.2014.32.15_Suppl.538 |
0.368 |
|
| 2014 |
Rampurwala MM, Choudhary A, Burkard ME. Abstract 2638: Novel synergy of radiosensitizer prodrug IPdR with Aurora kinase inhibitors in triple-negative breast cancer Cancer Research. 74: 2638-2638. DOI: 10.1158/1538-7445.Am2014-2638 |
0.416 |
|
| 2014 |
Burkard ME, Choudhary A, Lera RF, Fedenia R, Kanugh C, Laffin JJ, Zasadil LM, Weaver BA, Wisinski KB. Abstract 2526: Polyploidy: A new breast cancer subtype and a lead compound that targets it with high selectivity Cancer Research. 74: 2526-2526. DOI: 10.1158/1538-7445.Am2014-2526 |
0.389 |
|
| 2013 |
Wisinski KB, Tevaarwerk A, Bell M, Burkard ME, Eickhoff JC, Wilding G, LoConte NK, Traynor AM, Hoang T, Heideman J, Kolesar J, Liu G. A phase I study of MK-2206 in combination with lapatinib in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 31: 2607-2607. DOI: 10.1200/Jco.2013.31.15_Suppl.2607 |
0.301 |
|
| 2013 |
Fothergill A, Burkard M. Abstract 1927: Polyploidy across breast cancer subtypes. Cancer Research. 73: 1927-1927. DOI: 10.1158/1538-7445.Am2013-1927 |
0.355 |
|
| 2013 |
Zasadil LM, Burkard M, Weaver BA. Abstract 1750: Clinically relevant paclitaxel concentrations cause chromosome missegregation rather than mitotic arrest. Cancer Research. 73: 1750-1750. DOI: 10.1158/1538-7445.Am2013-1750 |
0.377 |
|
| 2013 |
Wisinski K, Burkard M, Njiaju U, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor A, Tevaarwerk A. Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P3-12-10 |
0.358 |
|
| 2013 |
Rocque G, Rampurwala M, Burkard M. PO84 VISUALIZING TREATMENT AND OUTCOMES IN METASTATIC BREAST CANCER The Breast. 22: S48. DOI: 10.1016/S0960-9776(13)70097-3 |
0.312 |
|
| 2012 |
Burkard ME, Santamaria A, Jallepalli PV. Enabling and disabling polo-like kinase 1 inhibition through chemical genetics. Acs Chemical Biology. 7: 978-81. PMID 22422077 DOI: 10.1021/Cb200551P |
0.307 |
|
| 2012 |
Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment. 131: 713-21. PMID 22065290 DOI: 10.1007/S10549-011-1862-Y |
0.362 |
|
| 2011 |
Lera RF, Burkard ME. Abstract 2986: Partial inhibition of Plk1 is cytotoxic despite normal spindle structure Cancer Research. 71: 2986-2986. DOI: 10.1158/1538-7445.Am2011-2986 |
0.372 |
|
| 2011 |
Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Zhang S, Kim K, Rishi S, Waack B, Wisinski K, Tevaarwerk A, Burkard M. P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-18-12 |
0.33 |
|
| 2011 |
Ehsani S, Tevaarwerk A, Wilke L, Neuman H, Beckman C, Becker J, Stettner A, Strigel R, Szalkucki L, Burkard M, Wisinski K. P4-11-21: A Retrospective Analysis of Women at Increased Lifetime Risk for Breast Cancer: Referral Patterns to Subspecialty Providers, Recommendations and Outcomes. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-11-21 |
0.31 |
|
| 2010 |
Burkard ME, Jallepalli PV. Validating cancer drug targets through chemical genetics. Biochimica Et Biophysica Acta. 1806: 251-7. PMID 20708654 DOI: 10.1016/J.Bbcan.2010.08.002 |
0.336 |
|
| 2001 |
Burkard ME, Xia T, Turner DH. Thermodynamics of RNA internal loops with a guanosine-guanosine pair adjacent to another noncanonical pair. Biochemistry. 40: 2478-83. PMID 11327869 DOI: 10.1021/Bi0012181 |
0.506 |
|
| 1999 |
Mathews DH, Burkard ME, Freier SM, Wyatt JR, Turner DH. Predicting oligonucleotide affinity to nucleic acid targets. Rna (New York, N.Y.). 5: 1458-69. PMID 10580474 DOI: 10.1017/S1355838299991148 |
0.505 |
|
| 1999 |
Burkard ME, Turner DH, Tinoco I. APPENDIX 2: Schematic Diagrams of Secondary and Tertiary Structure Elements Cold Spring Harbor Monograph Archive. 37: 681-685. DOI: 10.1101/087969589.37.681 |
0.443 |
|
| 1999 |
Burkard ME, Turner DH, Tinoco I. 10 The Interactions That Shape RNA Structure Cold Spring Harbor Monograph Archive. 37: 233-264. DOI: 10.1101/087969589.37.233 |
0.48 |
|
| 1998 |
Xia T, SantaLucia J, Burkard ME, Kierzek R, Schroeder SJ, Jiao X, Cox C, Turner DH. Thermodynamic parameters for an expanded nearest-neighbor model for formation of RNA duplexes with Watson-Crick base pairs. Biochemistry. 37: 14719-35. PMID 9778347 DOI: 10.1021/Bi9809425 |
0.509 |
|
| Show low-probability matches. |